Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Quetiapine augmentation outperforms lithium augmentation in long-term clinical and cost-effectiveness among adults with treatment-resistant depression, a 52-week trial finds.

Although a plethora of medications and therapies now exist for major depression, roughly one in three diagnosed patients ...

This is known as "treatment resistant" depression. They are aripiprazole ... thyroid hormone, low doses of stimulants, anticonvulsants, and other classes of antidepressants, such as tricyclic ...

Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

(Nature Metabolism) Meanwhile, positive phase III safety data for a proprietary formulation of the ADHD stimulant ...